Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for optimizing surgical outcomes in older adults (SPRY)
NCT03861767Phase 3Terminated
- Start
- Apr 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of liquid metformin (Aspargo Labs) in postoperative complications (10 arms). Primary endpoint: Hospital Free Days at 90 days. Started Apr 2019; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
postoperative complications
Beyond the preview
Go deeper on NCT03861767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861767.